Biohaven’s Genetic Disease Drug Achieves Key Trial Objective, According to Reuters

Biohaven Pharmaceuticals announced on Monday that it has achieved a key objective in a study assessing its drug for patients suffering from an inherited condition primarily impacting the brain.

The medication, called troriluzole, demonstrated a significant and clinically relevant reduction in the progression of Spinocerebellar Ataxia (SCA), as reported by the company.

Spinocerebellar Ataxia is a neurodegenerative disease that affects approximately 15,000 individuals in the United States, based on company estimates.

Following this announcement, Biohaven’s shares surged more than 20% in premarket trading.